Trial reportPolish archives of internal medicine2023
Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study.
Trial report in Polish archives of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06535529 (Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials.Heart failure reviews · 2024Pooled it
- Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024 · on this mapPooled it
- ADA-HF: acetazolamide as a chloride sparing diuretic in patients admitted to hospital with heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Trial
- Acetazolamide-induced metabolic acidosis in pediatric idiopathic intracranial hypertension: associations with bone mineral density, growth, and kidney function.Pediatric nephrology (Berlin, Germany) · 2026Article
- The 'Chloride Theory' for Heart Failure Pathophysiology: An Updated Narrative Review 2025.Cardiology and therapy · 2026Review
- Hypochloremia in Older Adults with Heart Failure: From Pathophysiology to Prognosis.Journal of clinical medicine · 2026Review
- Efficacy of combining acetazolamide with loop diuretics versus double dose loop diuretics for decongestion in patients with chronic kidney disease: a randomized controlled trial.Scientific reports · 2026Article
- Decongestion Strategies in Acute Heart Failure.Current heart failure reports · 2026Review
- Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A.Journal of clinical medicine · 2025Article
- Acetazolamide Therapy and Kidney Function in Persons with Nonalbuminuric Diabetes Mellitus Type 1.Journal of the American Society of Nephrology : JASN · 2025Article
- Effectiveness of Acetazolamide in Patients With Heart Failure: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- Acetazolamide Tolerance in Acute Decompensated Heart Failure: An Observational Study.Journal of clinical medicine · 2024Article
- Acetazolamide and Hydrochlorothiazide in Patients With Acute Decompensated Heart Failure: Insights From Recent Trials.Cardiology research · 2024Review
- Unlocking the Potential of Acetazolamide: A Literature Review of an Adjunctive Approach in Heart Failure Management.Journal of clinical medicine · 2024 · on this mapReview
- Acetazolamide Use in the Management of Refractory Acute Decompensated Heart Failure in the ICU.Discoveries (Craiova, Romania)Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDecongestion is a therapeutic target in acute heart failure (AHF). Acetazolamide is a diuretic that decreases proximal tubular sodium reabsorption, and may also reverse hypochloremia Objectives: We assessed the decongestive, natriuretic, and chloride‑regaining effects as well as the renal safety profile of oral acetazolamide (250 mg) used as an add‑on therapy in patients with AHF. PATIENTS AND
methodsThis prospective, randomized study was conducted at the Institute of Heart Diseases in Wrocław, Poland. It involved patients with AHF who were randomly assigned to receive either 250 mg of oral acetazolamide or standard care, and who underwent clinical and laboratory follow‑up for 3 consecutive days since the beginning of the treatment and at discharge.
resultsThe study population comprised 61 patients (71% men), of whom 31 (51%) were included in the acetazolamide group. The mean (SD) age of the patients was 68 (13) years. In comparison with the controls, the acetazolamide group demonstrated significantly higher cumulative diuresis after 48 and 72 hours since treatment implementation, negative fluid balance, weight loss after 48 hours of treatment, weight loss throughout the hospitalization, natriuresis, and serum chloride concentration. In terms of the renal safety profile, no increase in the creatinine concentration and urinary renal biomarker levels was noted.
conclusionsOral acetazolamide seems to be a valuable add‑on therapy that helps achieve comprehensive decongestion in patients with AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.